晨光生物：半年研发费用大幅增长主要是研发项目的结构发生变化

Core Viewpoint - The company, Morning Light Bio (300138), reported a significant increase in R&D expenses in the first half of the year, attributed to changes in the structure of R&D projects and a substantial rise in material costs [1] Group 1: R&D Expenses - R&D expenses have increased significantly due to the development of customized and application-oriented products [1] - The company emphasizes that technological innovation is the primary driving force behind its development [1] - The company plans to maintain substantial R&D investments while balancing expenses and profits to promote healthy growth [1]